GB202207116D0 - Method and Compositions for Tumorigenesis Inhibition - Google Patents

Method and Compositions for Tumorigenesis Inhibition

Info

Publication number
GB202207116D0
GB202207116D0 GBGB2207116.1A GB202207116A GB202207116D0 GB 202207116 D0 GB202207116 D0 GB 202207116D0 GB 202207116 A GB202207116 A GB 202207116A GB 202207116 D0 GB202207116 D0 GB 202207116D0
Authority
GB
United Kingdom
Prior art keywords
compositions
tumorigenesis
inhibition
tumorigenesis inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2207116.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadram Institute Bioscience
Original Assignee
Quadram Institute Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadram Institute Bioscience filed Critical Quadram Institute Bioscience
Priority to GBGB2207116.1A priority Critical patent/GB202207116D0/en
Publication of GB202207116D0 publication Critical patent/GB202207116D0/en
Priority to PCT/GB2023/051289 priority patent/WO2023223022A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2207116.1A 2022-05-16 2022-05-16 Method and Compositions for Tumorigenesis Inhibition Ceased GB202207116D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2207116.1A GB202207116D0 (en) 2022-05-16 2022-05-16 Method and Compositions for Tumorigenesis Inhibition
PCT/GB2023/051289 WO2023223022A1 (en) 2022-05-16 2023-05-16 Method and compositions for tumorigenesis inhibition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2207116.1A GB202207116D0 (en) 2022-05-16 2022-05-16 Method and Compositions for Tumorigenesis Inhibition

Publications (1)

Publication Number Publication Date
GB202207116D0 true GB202207116D0 (en) 2022-06-29

Family

ID=82156160

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2207116.1A Ceased GB202207116D0 (en) 2022-05-16 2022-05-16 Method and Compositions for Tumorigenesis Inhibition

Country Status (2)

Country Link
GB (1) GB202207116D0 (en)
WO (1) WO2023223022A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721707A2 (en) * 2007-05-17 2013-01-15 Genentech Inc crystal structures of neuropillin fragments and neuropillin-antibody complexes
NZ581286A (en) * 2007-05-17 2012-06-29 Genentech Inc CRYSTAL STRUCTURES OF Nrp1 and Nrp2 FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES
EP2823816A1 (en) * 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases
KR101551306B1 (en) * 2015-03-23 2015-09-09 아주대학교산학협력단 Neuropilin-1 specific binding peptides and its fusion protein, and use thereof

Also Published As

Publication number Publication date
WO2023223022A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
EP4136254A4 (en) Ace2-targeted compositions and methods for treating covid-19
EP4159728A4 (en) Preparation method for cdk4/6 inhibitor
GB202011871D0 (en) Composition and method
GB202207116D0 (en) Method and Compositions for Tumorigenesis Inhibition
GB202100997D0 (en) Composition and method
GB202016652D0 (en) Composition and method
EP4140981A4 (en) Methane-production inhibitor composition and method for inhibiting methane production
EP4149450A4 (en) Compositions and methods for hardening
GB202102310D0 (en) Composition and method
GB202100998D0 (en) Composition and method
GB202016644D0 (en) Composition and method
GB202211117D0 (en) Compositions and methods for non-immunogenecity
GB202217944D0 (en) Compositions and method
GB202310301D0 (en) Compositions and method and uses related thereto
GB202303250D0 (en) Method and compounds
GB202213792D0 (en) New compounds and method
GB202208130D0 (en) Composition and method
IL309345A (en) Compositions and methods for inhibiting the expression of tmigd2
GB202314126D0 (en) Compound and method
GB202302439D0 (en) Compound and method
GB202217829D0 (en) Method and compound
GB202314249D0 (en) Compositions and method for treating disease
EP4125925A4 (en) Compositions and methods for inhibiting type 1 collagen production
GB202306393D0 (en) Trna-based methods and related compositions
IL308133A (en) Compositions and methods for treating neuroendocrine tumors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)